Plant-derived insulin passes first human study

SemBioSys Genetics says that preliminary results of its first in man clinical study of SBS-1000, a recombinant human insulin manufactured  using its proprietary platform, shows that it is bioequivalent to a  recombinant human insulin with the expected safety profile.

The US firm specializing in the manufacture of high-value proteins and  oils in plant seeds says that SBS-1000 was bioequivalent to drug major  Eli Lilly's Humulin R, a human insulin widely-used in North America,  meeting all four of the endpoints.

According to SemBioSys, SBS-1000 showed pharmacokinetics and  pharmacodynamics indistinguishable from Lilly's Humulin R, as previously  shown in animals, and it was well tolerated at pharmacologically-active  doses.